Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chara Papadaki

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimenChara Papadaki, Dimitris Mavroudis, Maria Trypaki, et al.
Molecular and Cellular Biology|May 16, 2007
Transcriptional repressor erf determines extraembryonic ectoderm differentiationChara Papadaki, Maria Alexiou, Grace Cecena, et al.
Brain Research. Molecular Brain Research|October 16, 2003
The upstream regulatory region of the gene for the human homologue of the adhesion molecule TAG-1 contains elements driving neural specific expression in vivoMyrto Denaxa, Ourania Pavlou, Panayoula Tsiotra, et al.
Plos One|September 24, 2013
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideNiki Karachaliou, Chara Papadaki, Eleni Lagoudaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancerChara Papadaki, Maria Sfakianaki, Georgios Ioannidis, et al.
Oncotarget|March 9, 2019
Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancerChara Papadaki, Giannis Stoupis, Leuteris Tsalikis, et al.
Biomedicines|April 30, 2021
MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast CancerChara Papadaki, Konstantina Thomopoulou, Alexia Monastirioti, et al.
Cancers|August 14, 2025
MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung CancerChara Papadaki, Maria Mortoglou, Aristeidis E Boukouris, et al.
Cancers|February 25, 2022
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic ImplicationsMaria A Papadaki, Alexia Monastirioti, Christina A Apostolopoulou, et al.
Plos One|June 1, 2021
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution studyKonstantinos Rounis, Dimitrios Makrakis, Chara Papadaki, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimenChara Papadaki, Dimitris Mavroudis, Maria Trypaki, et al.
Molecular and Cellular Biology|May 16, 2007
Transcriptional repressor erf determines extraembryonic ectoderm differentiationChara Papadaki, Maria Alexiou, Grace Cecena, et al.
Brain Research. Molecular Brain Research|October 16, 2003
The upstream regulatory region of the gene for the human homologue of the adhesion molecule TAG-1 contains elements driving neural specific expression in vivoMyrto Denaxa, Ourania Pavlou, Panayoula Tsiotra, et al.
Plos One|September 24, 2013
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideNiki Karachaliou, Chara Papadaki, Eleni Lagoudaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancerChara Papadaki, Maria Sfakianaki, Georgios Ioannidis, et al.
Oncotarget|March 9, 2019
Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancerChara Papadaki, Giannis Stoupis, Leuteris Tsalikis, et al.
Biomedicines|April 30, 2021
MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast CancerChara Papadaki, Konstantina Thomopoulou, Alexia Monastirioti, et al.
Cancers|August 14, 2025
MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung CancerChara Papadaki, Maria Mortoglou, Aristeidis E Boukouris, et al.
Cancers|February 25, 2022
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic ImplicationsMaria A Papadaki, Alexia Monastirioti, Christina A Apostolopoulou, et al.
Plos One|June 1, 2021
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution studyKonstantinos Rounis, Dimitrios Makrakis, Chara Papadaki, et al.
Pageof 4